Richard H. Davis, Jr., PA-C
Division of Gastroenterology, Hepatology and Nutrition
University of Florida College of Medicine
Julia Pallentino, MSN, JD, ARNP-BC
Practice in Gastroenterology
Medical Group of North Florida
Satish S. Rao MD, PhD, FRCP (LON)
Professor of Medicine
Director, Neurogastroenterology and GI Motility
University of Iowa Carver College of Medicine
Iowa City, Iowa
Lawrence R. Schiller, MD, FACP, FACG
Digestive Health Associates of Texas
Program Director, Gastroenterology Fellowship
Baylor University Medical Center
Based on Symposia Presented in Philadelphia, Pennsylvania and Indianapolis, Indiana in Conjunction with the American Academy of Physicians Assistants (AAPA) and the American Academy of Nurse Practitioners, Monday, May 28, 2007 and June 22, 2007.
Chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C) are 2 of the most prevalent conditions treated in primary care practices in the United States and are among the most common indications for a referral to a gastroenterologist. There is overlap in the symptoms reported by patients with IBS-C and those who experience chronic constipation, making it challenging for the clinician to differentiate between these 2 disorders. Traditional treatment with laxatives and fiber supplements often does not provide adequate relief from symptoms and may lead to significant impairment of quality of life, higher health care utilization, and polypharmacy. However, recent advances in drug development have led to some promising agents that effectively treat chronic constipation. Program Developer/Facilitator
. Target Audience
This educational activity is designed to meet the needs of physicians, physician assistants, nurse practitioners and other health care professionals with an interest in the management of chronic constipation and IBS-C.
Upon completion of this educational activity, the participant should be able to:
Identify primary and secondary constipation causes, including transit time, dyssynergia, comorbidities, diet, and medication use.
Review diagnostic evidence to differentiate chronic constipation versus IBS-C.
Discuss disease burden, related complications, and quality of life issues associated with constipation.
Evaluate traditional and newer treatment options for constipation patients based on specific criteria of drug interactions, patient age, overall health, and other factors.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
This educational activity may contain discussion of published and/or investigational uses of agents used in the management of chronic constipation and IBS-C. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Richard H. Davis, Jr., PA-C discloses no actual or potential conflict of interest to this activity.
Julia Pallentino, MSN, JD, ARNP-BC discloses that she has received compensation as a member of speakers’ bureaus for Novartis and Takeda Pharmaceuticals North America, Inc.
Satish S. Rao MD, PhD, FRCP (LON) discloses that he has received compensation as a member of speakers’ bureaus for Novartis, AstraZeneca, Janssen, Salix Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and TAP Pharmaceuticals Inc., and as a member of advisory committees for Novartis, Takeda Pharmaceuticals North America, Inc., Smart Pill, sanofi-aventis, Theravance Inc., and Boehringer-Ingelheim.
Lawrence R. Schiller, MD, FACP, FACG discloses that he has received compensation as a consultant and speakers’ bureau member for Novartis, Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceuticals North America, Inc.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
Nurse Practitioners: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. AKH Inc. designates this educational activity for 1 contact hour which includes 0.25 pharmacology contact hour.
To receive credit, please read the monograph in its entirety, and complete and mail the post-test and program evaluation. This activity will require approximately one hour to complete. Commercial Support Statements
Supported by an educational grant from Sucampo Pharmaceuticals Inc. & Takeda Pharmaceuticals North America, Inc.
© 2007, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication and in the related educational event are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Sucampo Pharmaceuticals Inc. & Takeda Pharmaceuticals North America, Inc.. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.